The territory covers China including Mainland China, Taiwan, Hong Kong and Macau as well as other countries, including Thailand, Brazil and Russia.
3SBio president and CEO Dr Jing Lou said: "We are pleased to collaborate with PharmAbcine and look forward to moving Tanibirumab into clinical trials in China.
"3SBio continues to seek opportunities to expand our biologics pipeline, especially novel mAb candidates for refractory or metastatic cancers and other unmet medical needs, particularly in 3SBio’s core therapeutic areas of oncology and nephrology."
The company said that the license agreement included undisclosed upfront, milestone and royalty payments.
Angiogenesis is correlated with disease progression and poor prognosis in many tumors including colon, lung, breast and gastric cancers.
In most malignant tumors, such as gastric, liver, NSCLC, ovarian, brain, colorectal, and breast cancers, VEGF and KDR (VEGFR2) are over-expressed and their signaling is a major regulator for tumor angiogenesis.
Researchers from PharmAbcine have developed Tanibirumab that binds KDR and blocks binding of VEGFR ligands, including VEGF-A, VEGF-C and VEGF-D.